🇺🇸 FDA
Patent

US 9951132

Anti-prokineticin receptor (PROKR) antibodies and uses thereof

granted A61KA61K2039/505A61P

Quick answer

US patent 9951132 (Anti-prokineticin receptor (PROKR) antibodies and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Apr 24 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 19 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61P, A61P1/00, A61P1/04